Mounjaro’s approval status in Japan and how to use it correctly: a guide to the latest medical weight loss

  • Published:
  • Updated:
  • Written by the Hiro Clinic Medical Weight Loss editorial team
  • 40 min read
Medically reviewed by Dr. Hiroko Oka Reviewed byDr. Hiroko OkaCertified Member, Japanese Society of Internal Medicine Editorial policy
Mounjaro’s approval status in Japan and how to use it correctly: a guide to the latest medical weight loss

Bottom line firstShort on time? Just read this

  • In Japan, Mounjaro is approved as a treatment for type 2 diabetes; its use for treating obesity is currently limited to self-pay treatment not covered by health insurance
  • Mounjaro’s own international randomized controlled trials (the SURMOUNT trial series) have all shown substantial weight loss
  • Mounjaro works best when combined with lifestyle improvements rather than used on its own

What you’ll learn in this article

  • Mounjaro’s approval status in Japan and where self-pay treatment fits in
  • The actual weight-loss figures shown in international clinical trials
  • Precautions to check when using it as self-pay treatment
  • The outlook for future approval and health insurance coverage

Introduction

In Japan, Mounjaro is approved as a treatment for type 2 diabetes; its use for treating obesity is currently limited to self-pay treatment not covered by health insurance. In recent years, one drug drawing attention as a medical intervention for obesity and overweight is Mounjaro. Mounjaro is a dual agonist that acts as both a GLP-1 (glucagon-like peptide-1) receptor agonist and a GIP receptor agonist, and appetite-suppressing and weight-loss effects have been reported. This article explains Mounjaro’s approval status in Japan, the clinical evidence, indications for use and the outlook for the future.

What is Mounjaro?

Mounjaro is the world’s first dual agonist that acts simultaneously on the receptors for two incretin hormones, GIP and GLP-1. It was originally developed as a treatment for type 2 diabetes. GLP-1 is a hormone released from the digestive tract and is known to curb the rise in blood sugar after eating, promote a feeling of fullness and suppress appetite by slowing gastric emptying.

Applying these actions, it is sometimes used to support weight loss in patients with obesity or overweight. It is drawing attention in particular as one option when lifestyle improvements alone have not produced enough weight loss. However, results vary from person to person, and not everyone will get the same results.

Main mechanisms of action

  1. Appetite suppression: acts on the hypothalamus in the brain to increase the feeling of fullness.
  2. Slower gastric emptying: slows the digestion and absorption of food and curbs sharp rises in blood sugar after meals.
  3. Blood sugar improvement: promotes insulin secretion and helps improve glucose metabolism.

Approval status in Japan

Currently, Mounjaro is officially approved in Japan only for the treatment of type 2 diabetes and has not been approved for the treatment of obesity disease. For this reason, when it is used for people with obesity disease, it is mainly provided as self-pay treatment (not covered by health insurance), and you pay the full cost yourself.

The key points of its approval status in Japan as of 2026 are as follows.

ItemStatus
Approved forPatients with type 2 diabetes
FormInjection (given once weekly)
Health insurance coverageDiabetes treatment only
Approval for obesity diseaseNone (mainly provided as self-pay treatment)
CostFull cost paid by the patient when used to treat obesity

Overseas, the U.S. Food and Drug Administration (FDA) approved tirzepatide, the active ingredient of Mounjaro, as an obesity medication in 2023 (product name Zepbound), and significant weight loss has also been reported in international clinical trials [1]. Clinical research is also under way in Japan, and approval for obesity disease may be obtained in the future, but no clear timing for approval has been indicated at this point.

Clinical evidence for Mounjaro

Weight-loss effect

Mounjaro’s own international randomized controlled trials (the SURMOUNT trial series) have all shown substantial weight loss.

  • SURMOUNT-1 trial [2]: in 2,539 adults with obesity or overweight without type 2 diabetes who received the drug for 72 weeks, average weight loss of 20.9% in the highest-dose (15 mg) group, 19.5% in the 10 mg group and 15% in the 5 mg group was reported.
  • SURMOUNT-2 trial [3]: in a trial of adults with obesity or overweight who also had type 2 diabetes, weight loss of more than 10% was confirmed depending on dose, along with improvement in HbA1c.

These trials showed that greater weight loss is achieved when combined with guidance on lifestyle improvement (diet and exercise). Note that all of the above are averages from clinical trials, and actual effects and the amount of weight lost vary from person to person. Please note that this does not guarantee that you will “definitely lose this much weight.”

Safety

Mounjaro’s main side effects are gastrointestinal symptoms, and nausea, vomiting, diarrhea and constipation have been reported. In rare cases, risks of pancreatitis and gallbladder disease have also been noted. When it is used in Japan, careful monitoring by a doctor is required, with reference to clinical data from overseas.

Possibility of use in Japan

Although Mounjaro is not officially approved for the treatment of obesity disease, there are cases where it is used under the following conditions.

  1. Introduction as self-pay treatment
    Some clinics in Japan offer Mounjaro as self-pay treatment for the purpose of treating obesity, based on its approval for diabetes treatment. In this case, the doctor decides the dose, dosing interval and so on with reference to overseas guidelines and clinical research.
  2. Participation in clinical trials or clinical research
    Clinical trials of Mounjaro for obesity disease are also under way in Japan, and in some cases you may be able to use it by taking part in research.
  3. Use of overseas approval data
    There are moves to build up evidence for introduction in Japan based on the FDA-approved obesity treatment data. Collecting safety and efficacy data in Japanese people in particular will be key to obtaining approval in the future.
Image of a person who succeeded in losing weight

Nutrition and lifestyle while using Mounjaro: a doctor’s tips for getting the most out of it and preventing rebound

The bottom line firstShort on time? Just read this partTo maintain Mounjaro&#...

Mounjaro side effects: types, frequency and how to manage them, explained by a doctor

The bottom line firstShort on time? Just read this part Mounjaro’s side...

Future outlook

Approval of Mounjaro for the treatment of obesity disease in Japan becomes more likely as Japanese data accumulate and are reflected in guidelines.

  1. Accumulation of Japanese clinical data
    Once enough safety and efficacy data in Japanese people are obtained, approval review by the Ministry of Health, Labour and Welfare will move forward.
  2. Inclusion in obesity treatment guidelines
    If specialist societies such as the Japan Society for the Study of Obesity include it in their guidance for use, awareness in clinical practice will increase.
  3. Possibility of health insurance coverage
    If approval for the treatment of obesity disease is obtained in the future, a shift from self-pay treatment to insurance-covered care may become possible, allowing it to be used at lower financial burden.
  4. Comprehensive treatment through multidisciplinary collaboration
    Collaboration among doctors, registered dietitians, exercise therapists and others makes it possible to achieve sustained weight management that the drug alone cannot provide.

Not sure if it suits you? Start with a consultation.

A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.

No consultation fee (first & follow-up visits)Online consultation available

Precautions for use

When using Mounjaro, please keep the following points in mind.

  • Managing gastrointestinal symptoms: because nausea and vomiting tend to occur when starting treatment, the dose is increased gradually (“stepwise dose escalation”).
  • Interactions with other medications: caution is needed especially when used together with oral diabetes medications or anticoagulants.
  • Checking medical history: people with pancreatitis, gallstones or kidney problems need to use it with caution.
  • No use on your own judgment: even as self-pay treatment, it must be used under a doctor’s supervision. Please avoid obtaining it through personal import or using it on your own judgment.

The significance of Mounjaro from a healthcare professional’s perspective

For healthcare professionals, Mounjaro is a new option for people who have had difficulty getting results with conventional weight-loss support. In our practice, we sometimes hear from people who say “I couldn’t keep up treatment at another clinic,” and we feel that having more options is meaningful in itself. In counseling, we are also often asked about the cost and the fact that it is self-pay treatment, and each time we make a point of carefully explaining that it is not covered by health insurance and that results vary from person to person. The following points in particular are drawing attention.

  1. Safety evaluation premised on medication management
    Clinical data from overseas are advancing the evaluation of cardiovascular risk and effects on improving glucose metabolism.
  2. Diverse applications in clinical practice
    It may help reduce the risk not only for patients with diabetes but also of lifestyle-related diseases associated with obesity, such as dyslipidemia and high blood pressure.
  3. Greater patient motivation
    In some cases, the visible change of weight loss leads to more motivation to improve lifestyle habits.

Research trends

Research on Mounjaro is also actively under way in Japan. The following themes in particular are drawing attention.

  • Verifying the weight-loss effect in Japanese people
    Because of differences in physique and eating habits, data from overseas trials may not apply directly in Japan, so verification of the effect in Japanese people is needed.
  • Evaluating long-term safety
    The incidence of gastrointestinal symptoms, pancreatitis, gallstones and so on during use over several years is being tracked, building up safety data toward approval in Japan.
  • Confirming cardiovascular risk reduction
    Research is also under way to verify whether weight loss helps prevent cardiovascular disease, which would be an indicator that raises the social significance of obesity treatment.

How Mounjaro works | A doctor explains its dual action on GIP and GLP-1

Mounjaro differs in its mechanism of action from existing GLP-1 receptor agon...

Mounjaro clinical data and weight-loss effects: the latest evidence explained

Key points firstShort on time? Just read this Mounjaro is a drug whose effect...

Combining it with lifestyle management at home

Mounjaro works best when combined with lifestyle improvements rather than used on its own.

  • Diet management
    Aim for nutritionally balanced meals, and in particular adjust how much carbohydrate and fat you eat.
  • Exercise therapy
    Combining aerobic exercise and strength training helps maintain basal metabolism and supports fat burning.
  • Behavior change support
    Recording your weight, meals and exercise in a diary or app and improving your self-management skills helps you maintain weight loss over the long term.

On X (formerly Twitter), too, there are posts from users of Mounjaro reporting lifestyle adjustments such as “I started strength training for my legs and abdomen while getting enough protein.” These are only personal records and do not guarantee results, but the attitude of improving lifestyle habits instead of relying on the drug alone matches the points doctors also recommend.

About self-pay treatment and off-label use

Self-pay treatment
Medical weight loss is self-pay treatment (paid in full by the patient) and is not covered by public health insurance.
Off-label use
Using medicines for weight management or weight loss may be off-label use, outside the indications approved in Japan.
Relief System for Adverse Drug Reactions
With off-label use, health damage such as a serious side effect may not be covered by Japan’s Relief System for Adverse Drug Reactions.
Individual differences and the doctor’s judgment
Effects and side effects vary from person to person. A doctor decides after a consultation whether you can use a medicine and which medicine and dose are appropriate. Please tell us in advance about any symptoms, chronic conditions or medicines you are taking.

Frequently asked questions (FAQ)

QCan I get Mounjaro prescribed in Japan for weight loss?
A

It has not yet been approved for the treatment of obesity disease itself, but you may be able to get a prescription at medical facilities that offer it as self-pay treatment. Please consider it with the understanding that health insurance does not apply and you pay the full cost yourself.

QIs it okay to buy Mounjaro through personal import?
A

We do not recommend personal import because quality and safety cannot be confirmed. There is a risk of counterfeit products and a risk of not being under a doctor’s supervision, so always get a prescription through a medical facility.

QWill Mounjaro be covered by health insurance in the future?
A

If approval for the treatment of obesity disease is obtained in Japan, a shift to insurance-covered care may become possible. However, no specific timing for approval has been indicated at this point, and it is expected to continue to be provided as self-pay treatment for the time being.

QDo overseas clinical trial data apply directly to Japanese people?
A

Because of differences in physique and eating habits, overseas data do not necessarily apply directly. Verification of efficacy and safety in Japanese people is still continuing.

QCan I use Mounjaro if I don’t have diabetes?
A

Approval in Japan is limited to the treatment of type 2 diabetes, but self-pay clinics also prescribe it to people without diabetes. Whether you can use it is decided by a doctor’s examination and assessment.

Summary

Mounjaro is a drug that can be one option in the treatment of obesity disease. In Japan, it is currently approved only for diabetes treatment, but given its track record in treating obesity disease overseas and the progress of clinical research in Japan, future approval and wider use are anticipated.

What matters for patients is not to use Mounjaro on its own, but to combine it with lifestyle improvements under a doctor’s supervision, and to consider treatment with a correct understanding that it is self-pay treatment and of the costs involved. For healthcare professionals, too, further data are anticipated as it offers a new option for patients who do not get enough results from conventional weight-loss methods.

References

  1. FDA. FDA Approves New Medication for Chronic Weight Management. 2023.
    See the official FDA announcement
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. (SURMOUNT-1 trial)
    Read the original paper (NEJM)
  3. Garvey WT, et al. Tirzepatide for weight reduction in patients with type 2 diabetes. Lancet. 2023;402:613-626. (SURMOUNT-2 trial)
    Read the original paper (The Lancet)
  4. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025;48(Suppl. 1):S123-S141.
    Read the original paper (Diabetes Care)

Medically reviewed by: Dr. Hiroko Oka (Chair, Fukubikai Medical Corporation / Certified Member, Japanese Society of Internal Medicine)

Who to contact if you have side effects | When to see a doctor

If you have any of the following symptoms, please contact us rather than waiting to see on your own judgment. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly gastrointestinal symptoms. Most are mild, but in rare cases they can be serious.

SymptomsPossible causeWhat to do
Continuing nausea or vomitingGastrointestinal symptoms. The most common side effectPlease contact us if you remain unable to keep fluids down
Severe abdominal pain (pain radiating to the back)Possible acute pancreatitisStop the medication immediately and see a doctor
Cold sweats, palpitations, intense hunger, feeling confused or drowsyHypoglycemiaTake sugar right away and contact us
Skin rash, difficulty breathing, swelling of the face or throatAllergic reactionSee a doctor immediately

Contact: 0120-241-929 (hours 9:00–18:00)
If your symptoms are severe outside these hours, please go to your nearest emergency medical facility.

Direct phone numbers for each clinic are listed on the clinic information page.

References

The information on medications in this article is based on the following official sources. For details on dosage and administration and side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert” (Japanese)
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF, Japanese)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases” (Japanese)

When Mounjaro is used for purposes other than obesity disease, it is self-pay treatment and public health insurance does not apply. Effects and side effects vary from person to person.

Reviewing doctor: Hiroko Oka
Reviewing doctor

Hiroko OkaDirector, Hiro Clinic Kawaguchi (physician)

Japanese Society of Internal Medicine Chairman, Medical Corporation Fukubikai / Certified Member, Japanese Society of Internal Medicine After graduating from Toho University School of Medicine in 1997, joined the Department of Internal Medicine at Keio University School of Medicine. Gained experience in internal medicine at university and general hospitals, and opened Hiro Clinic in 2008. About our medical review and editorial policy

You may also like

Back to all articles

Ask our AI chat AI chat